What GLP-1 is and how it works in your body
The hormone your gut produces to regulate glucose: where its receptors sit, what it does, why it lasts minutes, and why analogues exist.
GLP-1 is a hormone your own gut produces. Its full name is glucagon-like peptide 1, it is secreted by L-cells in the ileum, and it is a 37-amino-acid peptide. Its receptors are not confined to the pancreas: they also appear in the central and peripheral nervous systems, the heart and blood vessels, the kidneys, the lungs, and the gastrointestinal mucosa. That mechanism is what medical treatments acting on this receptor make use of; see the medical GLP-1 weight loss programme.
Where it acts and what it does
When GLP-1 binds to its receptor, four effects are described in the literature:
- it stimulates pancreatic islet β-cells to secrete insulin;
- it inhibits glucagon release by α-cells;
- it increases satiety;
- it delays gastric emptying.
All four occur in a glucose-dependent manner. That detail matters because it means the action is modulated by the glucose level present, rather than being a fixed switch.
Why the hormone you already have does not work as a treatment
Endogenous GLP-1 has a very short half-life. The enzyme dipeptidyl peptidase-4, known as DPP-4, degrades and inactivates it rapidly.
The problem is therefore not the molecule's potency but how long it stays available. To prolong stimulation of the GLP-1 receptor, synthetic analogues are needed that resist that degradation. That is why this family of medicines exists, and it is not an incidental design detail. The work of making it last is explained in why some peptides are given once a week.
From hormone to analogues
GLP-1 analogues are one specific case inside a broader class, that of therapeutic peptides. The first was approved by the FDA in 2005. Others followed in 2009, 2013, 2014, and 2017. That sequence of years reflects the work of modifying the molecule to preserve its effect while gaining stability.
Within this family, the longer-acting versions have two practical consequences: they are administered less frequently, and they show better treatment adherence.
What has been studied beyond glucose
The distribution of the receptors explains why research has looked at systems beyond metabolism. There are studies on kidney function, on the cardiovascular system, and on bone in patients with type 2 diabetes.
Precision matters here about the limits of that knowledge. The reference review states explicitly that the extent to which those effects are mediated by the GLP-1 receptor itself remains to be determined. In other words: there are findings, and there is an open question about the mechanism.
Known adverse effects
The most frequent adverse reactions the literature describes for this family are gastrointestinal: mainly nausea, vomiting, and diarrhoea, along with injection-site reactions. The same review notes that, within the family, longer-acting versions show fewer adverse effects, lower administration frequency, and better adherence.
That is why they are prescription medicines with clinical follow-up, and not over-the-counter products.
What this means if you are considering treatment
That GLP-1 is a hormone your body already produces does not make it something to take on your own. It acts on receptors that serve real functions across several organs, and that is precisely what makes follow-up necessary.
On compounded formulations: the base active ingredient holds FDA approval in its brand-name reference medicines. Personalised compounded formulations are prepared and dispensed by state-licensed 503A pharmacies under strict individualised medical prescription following a clinical consultation. A compounded medicine is not an FDA-approved equivalent of a brand-name product.
Frequently asked questions
Is GLP-1 the same as insulin?
No. They are two distinct peptides with related functions. Insulin is the hormone that lowers blood glucose; GLP-1 is the signal that induces the pancreas to secrete it, among other actions.
So what is semaglutide?
It is a GLP-1 receptor analogue, meaning a molecule designed to activate that same receptor and to last longer in the body than the natural hormone does.
Why does natural GLP-1 last so little?
Because the enzyme DPP-4 degrades and inactivates it rapidly. That is the reason analogues exist.
Does it affect parts of the body other than the pancreas?
Its receptors appear in the nervous system, the heart, the blood vessels, the kidneys, the lungs, and the gastrointestinal mucosa. Research has explored effects across several of those systems, and the extent to which they depend on the receptor is still under study.
Can I take GLP-1 without a prescription?
No. These are prescription medicines with documented adverse effects, and their indication depends on an individual clinical assessment. Individual results vary according to each person's biological response.
If you want to know whether GLP-1 treatment is right for you
A licensed professional reviews your history, your medication, and your background before any treatment is considered, and follow-up continues after the initial consultation.
Start your clinical evaluation →
Sources
- Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Wang X, Wang R, Fu C. Therapeutic peptides: current applications and future directions. *Signal Transduction and Targeted Therapy.* 2022;7(1):48. doi:10.1038/s41392-022-00904-4. Licence CC BY 4.0.
- FDA. Compounding Laws and Policies. `https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies`
Medical Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Always consult your physician before making any changes to your medication or lifestyle regimen.
Interested in personalized medical protocols?
Explore our compounded GLP-1, 503A Peptides, and hormone optimization options.